Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 28 September 2023, 16:05 HKT/SGT
Share:
    

Source: Eisai
Eisai Launches New "Innovation" Page on Corporate Website

Eisai Co., Ltd. announced today that it has launched a new “Innovation” page on its corporate website. The "Innovation" page is comprised of four sections: "Research & Development (R&D)," "Ecosystem," "Open Innovation," and "Corporate Venture Capital," which are the core of Eisai’s innovation creation. Each part introduces information such as Eisai’s strengths, originality, and the status of specific initiatives.

"Innovation" top page www.eisai.com/innovation/index.html

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept, (also known as our human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities.

On the newly established "Innovation" page, Eisai has enhanced information on policies, characteristics, and examples of initiatives for innovation creation aimed at realizing it’s corporate concept. The “R&D” section contains new contents, such as an overview of the Deep Human Biology Learning (DHBL) drug discovery and development system, which was established last year, track records of Eisai’s long-term commitment to dementia, oncology and tropical diseases, and the current status of digital technology application in R&D settings. In addition, the "Ecosystem" section explains Eisai’s policy of evolving into an hhceco (hhc concept + ecosystem) company to empower people to “realize their fullest lives” how they would like, from the time that they are in good health up to their final moments, and the dementia hhceco model on which Eisai is focusing. Moreover, the “Open Innovation” and “Corporate Venture Capital” sections introduce their respective business policies and achievements, and an inquiry page for new partnering opportunities has been established.

Eisai will continue to disclose information in a proactive and easy-to-understand manner through our corporate website and communicate with all of our stakeholders to help them understand our corporate concept and business activities.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Oct 2, 2024 10:28 HKT/SGT
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia
Sept 24, 2024 15:06 HKT/SGT
Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis
Sept 24, 2024 14:01 HKT/SGT
Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements
Sept 17, 2024 09:08 HKT/SGT
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Sept 5, 2024 15:59 HKT/SGT
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
Sept 2, 2024 14:12 HKT/SGT
Eisai Announces Status Relating to Acquisition of Own Shares
Aug 22, 2024 18:54 HKT/SGT
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
Aug 14, 2024 08:59 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
Aug 6, 2024 12:15 HKT/SGT
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
July 31, 2024 12:59 HKT/SGT
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: